Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Teva Pay-For-Delay Plausible; Judge Finds Payments Exceed Litigation Costs

This article was originally published in The Pink Sheet Daily

Executive Summary

Focused on $300 million in payments Cephalon made to generic firms to settle Provigil patent suits, case is second to proceed to trial since Supreme Court’s Actavis decision.

You may also be interested in...

Teva’s Pay-For-Delay Settlement Restricts Brand-Generic Deals

$1.2 billion agreement resolving Provigil litigation with FTC blocks Teva from entering business deal with competitor until 30 days after patent settlement that restricts generic entry, sets $7 million cap on litigation savings.

‘Pay-For-Delay’ Deals Likely Put On Hold Themselves After Cipro Ruling

California Supreme Court finds patents are ‘probablistic rather than ironclad,’ and outlines four-prong antitrust test that further complicates brand/generic deal making.

Teva Settles Provigil Pay-For-Delay Class Action; Will FTC Deal Follow?

Teva plays it safe in $512 million agreement with direct purchasers, even though AstraZeneca won a jury verdict in similar suit, the first to go to trial since Supreme Court’s FTC v. Actavis decision.

Related Content


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts